The use of ‘omic’ analysis for identification of survival features has had the most success in grade II/III glioma where distinct subtypes of gliomas can be defined by combinations of mutations in isocitrate dehydrogenase (IDH1-R132H), telomerase (TERT) and 1p/19q chromosomal co-deletion [7]. This evidence concerns the gene TERT and central nervous system cancer.